ACADIA Pharmaceuticals Inc (OQ:ACAD)

Business Focus: Biotechnology & Medical Research

Apr 24, 2024 04:05 pm ET
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Apr 22, 2024 09:04 am ET
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
Apr 19, 2024 04:05 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units (“RSUs”) to six new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 17, 2024 04:05 pm ET
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
Apr 05, 2024 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Apr 02, 2024 04:05 pm ET
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of
Apr 01, 2024 04:05 pm ET
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.
Apr 01, 2024 07:00 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 28, 2024 03:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 26, 2024 03:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 25, 2024 04:30 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 24, 2024 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of the securities laws.
Mar 22, 2024 07:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 20, 2024 07:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 19, 2024 03:30 am ET
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 18, 2024 03:30 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 18, 2024 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 15, 2024 04:05 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Mar 15, 2024 03:00 am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 14, 2024 03:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 13, 2024 04:05 pm ET
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.
Mar 13, 2024 04:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 12, 2024 05:45 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ:ACAD) for violations of the securities laws.
Mar 11, 2024 04:05 pm ET
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.
Mar 07, 2024 04:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Feb 29, 2024 09:05 am ET
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time.
Feb 28, 2024 03:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Feb 27, 2024 04:05 pm ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023.
Feb 22, 2024 08:16 pm ET
ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
​The Portnoy Law Firm advises ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD) investors that the law firm has initiated an investigation on behalf of investors that lost money on their ACADIA stock. ACADIA investors are...
Feb 22, 2024 09:22 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Feb 21, 2024 04:05 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,823 shares of common stock and 34,087 restricted stock units (“RSUs”) to seventeen new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Feb 13, 2024 04:05 pm ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Jan 30, 2024 08:48 pm ET
Acadia Announces Additions to Executive Team
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced two new appointments to its executive team. Jennifer J. Rhodes is joining the company as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution, both effective immediately. Following a transi
Jan 19, 2024 04:05 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 9, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 39,169 shares of common stock and 13,895 restricted stock units (“RSUs”) to eleven new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 18, 2024 04:05 pm ET
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is saddened to announce the passing of its former President, Srdjan (Serge) Stankovic M.D., M.S.P.H. Serge passed away peacefully on December 29, 2023, following a prolonged illness.
Dec 21, 2023 04:05 pm ET
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session.
Dec 18, 2023 04:05 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 33,647 shares of common stock and 20,146 restricted stock units (“RSUs”) to eight new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 13, 2023 09:24 pm ET
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s Order, the Court
Dec 13, 2023 01:41 pm ET
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The court ruled in favor of Acadia on all grounds. The ruling came in Acadia’s litigation ag
Dec 11, 2023 09:00 pm ET
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) on behalf of long-term stockholders following a class action complaint that was...
Dec 10, 2023 04:13 pm ET
ACADIA SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. (“Acadia”) (NASDAQ: ACAD) on behalf the company’s long-term investors. Recently an amended securities fraud complaint was filed against Acadia on behalf of certain...
Nov 30, 2023 09:05 am ET
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the United States.1-4 The most common symptom is hyperphagia, which is an unrelenting lack of satiety. Other defining features of PWS may include altered metabolism, developmental delays, behavioral challenges and moderate cognitive deficits.
Nov 27, 2023 09:05 am ET
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Of the more than 6.5 million people in the United States living with Alzheimer’s disease (AD), approximately 30% will experience psychosis, commonly consisting of hallucinations and delusions.1-3
Nov 21, 2023 05:00 pm ET
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement.
Nov 14, 2023 04:12 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 3, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 10,481 shares of common stock and 6,275 restricted stock units (“RSUs”) to nine new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 02, 2023 04:05 pm ET
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023.
Oct 31, 2023 04:05 pm ET
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the Guggenheim Securities 5th Annual Inflammation & Immunology (I&I) Conference on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time.
Oct 23, 2023 09:05 am ET
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
“As a parent, the most important thing we can do is to ensure that our children feel supported no matter what challenges they may have to face,” said Matthew and Anna Heimburger, parents to Lucy, who lives with Rett syndrome, and her two older brothers, Fischer and Mason. “In our family’s experience, Lucy’s brothers have been integral to her ongoing care and they also inspire her to try new things, find new interests, and keep her engaged in the world around her. The Rett Sibling Scholarship recognizes siblings' commitment to their loved ones and is an important reminder that their dreams, too
Oct 19, 2023 04:05 pm ET
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Oct 18, 2023 05:00 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 4, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 145,119 shares of common stock and 38,559 restricted stock units (“RSUs”) to 19 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 22, 2023 06:23 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 8, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,749 shares of common stock and 14,306 restricted stock units (“RSUs”) to 14 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 19, 2023 04:05 pm ET
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee. He will report t
Aug 30, 2023 04:05 pm ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Aug 14, 2023 04:05 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 1, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 40,612 shares of common stock and 14,990 restricted stock units (“RSUs”) to 16 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 02, 2023 04:05 pm ET
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2023.
Aug 01, 2023 07:30 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 18, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 19,903 shares of common stock and 11,988 restricted stock units (“RSUs”) to 16 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 24, 2023 04:05 pm ET
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia.
Jul 19, 2023 04:04 pm ET
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Jul 13, 2023 04:05 pm ET
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. In April of this year, Acadia launched trofinetide in the United States under the brand name DAYBUE as the first and only drug approved for the treatment of Rett syndrome.
Jun 26, 2023 05:00 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 153,615 shares of common stock and 56,399 restricted stock units (“RSUs”) to 28 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 13, 2023 04:05 pm ET
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia (a false and unrelenting state of starvation) in Prader-Willi syndrome (PWS). Acadia acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022.
Jun 08, 2023 11:10 am ET
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE™ in patients with Rett syndrome five to 20 years of age.
Jun 01, 2023 09:04 am ET
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY.
May 24, 2023 09:00 pm ET
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) on behalf of long-term stockholders following a class action complaint that was filed against Acadia on April 19, 2021 with a Class Period from June 15, 2020 to April 4, 2021. Our investigation concerns whether the board of directors of Acadia have breached their fiduciary duties to the company.
May 24, 2023 08:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc. (ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia”) (NASDAQ: ACAD) on behalf of certain investors who purchased shares of the Company’s stock between September 9, 2019 and...
May 08, 2023 04:05 pm ET
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.
May 05, 2023 04:04 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (“RSUs”) to 44 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee of Acadia’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
May 02, 2023 09:04 am ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Apr 25, 2023 09:04 am ET
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Monday, May 8, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Apr 20, 2023 09:04 am ET
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Mass.
Apr 17, 2023 09:04 am ET
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States. DAYBUE has demonstrated the potential to improve the signs and symptoms of Rett syndrome. DAYBUE was approved by the U.S. Food and Drug Administration (FDA) on March 10, 2023, and is the first and only drug approved by the FDA for the treatment of Rett syndrome.
Apr 11, 2023 09:04 am ET
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time.
Mar 10, 2023 09:45 pm ET
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome.
Mar 03, 2023 07:30 pm ET
ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).
Feb 27, 2023 04:05 pm ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022.
Feb 14, 2023 04:05 pm ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Feb 13, 2023 04:15 pm ET
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 10, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common stock and 97,251 restricted stock units (“RSUs”) to 19 new employees under Acadia’s 2023 Inducement Plan. Among such awards was a non-qualified stock option to purchase 237,296 shares of common stock and RSUs covering 50,655 shares of common stock granted to Douglas J. Williamson, Acadia’s newly appointed Executive Vice President, Head of Research &
Jan 09, 2023 09:00 am ET
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development (R&D). Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr. Srdjan Stankovic, whose planned retirement was announced last year.
Jan 03, 2023 09:00 am ET
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Aty
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics
Dec 21, 2022 04:05 pm ET
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.
Nov 25, 2022 10:50 pm ET
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).
Nov 11, 2022 09:54 pm ET
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
NEW ORLEANS, Nov. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).
Nov 08, 2022 04:05 pm ET
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Nov 02, 2022 04:05 pm ET
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
Oct 31, 2022 08:00 pm ET
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).
Oct 27, 2022 04:05 pm ET
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its President, Srdjan (Serge) Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time basis.
Oct 20, 2022 04:05 pm ET
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Oct 13, 2022 07:30 am ET
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors. Dr. Ndu is a biopharma executive with more than 15 years of experience in regulatory affairs and clinical development.
Oct 04, 2022 07:30 am ET
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
Acadia Pharmaceuticals today announced the launch of Rett Revealed, a new awareness campaign that will highlight the lives of Rett patients through a photo mosaic designed by Emily Shifflet, a 27-year-old eye-gaze artist living with Rett syndrome. In honor of Rett syndrome awareness month, this October members of the community are encouraged to submit their photos capturing meaningful moments in their lives to
Sep 12, 2022 07:30 am ET
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The FDA has granted a priority review and assigned a PDUFA (Prescription Drug User Fee Act) action date of March 12, 2023. The FDA has also informed the company that at this time they are not planning to hold an Advisory Committee meeting.
Sep 01, 2022 09:03 am ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Aug 08, 2022 04:05 pm ET
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
Aug 04, 2022 11:05 pm ET
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheime
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
Jul 25, 2022 04:05 pm ET
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 8, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Jul 21, 2022 08:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
NEW YORK, July 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages
Jul 18, 2022 04:07 pm ET
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
Jul 13, 2022 07:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damages
Jul 01, 2022 07:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
Jun 17, 2022 08:00 pm ET
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The PDAC voted 9 to 3 that the evidence presented does not support a conclusion that pimavanserin is effective for the treatment of hallucinations and delusions in the ADP population.
Jun 17, 2022 07:05 am ET
Acadia Pharmaceuticals Stock Trading Halted Today
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company’s common stock.
Jun 15, 2022 10:55 am ET
Thinking about buying stock in Nio, Roblox, ACADIA Pharmaceuticals, Gevo, or AeroClean Technologies?
NEW YORK, June 15, 2022 /PRNewswire/ --  InvestorsObserver issues critical PriceWatch Alerts for NIO, RBLX, ACAD, GEVO, and AERC.
May 04, 2022 04:05 pm ET
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.
May 03, 2022 04:05 pm ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
May 02, 2022 04:05 pm ET
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psycho
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022. The target action date for the application is August 4, 2022.
Apr 21, 2022 09:00 am ET
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 4, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Apr 18, 2022 04:05 pm ET
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, ACP-044 400 mg four times daily and placebo treatment arms, was not met.
Mar 22, 2022 09:00 am ET
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.
Mar 10, 2022 04:05 pm ET
Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 1st Annual Needham Virtual Neuroscience Forum on Wednesday, March 16, 2022 at 3:20 p.m. Eastern Time.
Mar 09, 2022 08:30 am ET
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The FDA’s Division of Psychiatry has also advised the company that it is planning to hold an Advisory Committee meeting in connection with its review.
Mar 03, 2022 09:00 am ET
Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.
Feb 28, 2022 04:05 pm ET
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.
Feb 16, 2022 09:00 am ET
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA).
Feb 14, 2022 09:00 am ET
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 28, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Feb 11, 2022 09:00 am ET
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time.
Dec 22, 2021 09:00 am ET
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 10:30 a.m. Eastern Time, followed by a question and answer session.
Dec 20, 2021 04:05 pm ET
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis (ADP). Resubmission of the sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022.
Dec 14, 2021 09:00 am ET
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately. Mr. Schneyer has served as the company’s interim CFO since September 2021, while retaining his responsibilities as Acadia’s head of business development and Chief Business Officer. Mr. Schneyer’s responsibilities as CFO will include the functional areas of finance, accounting, investor relations, and business development. Mr. Schneyer will continue to report to Steve Davis, Chief Executive Officer, and will remain a member
Dec 07, 2021 07:30 am ET
Thinking about buying stock in ACADIA Pharmaceuticals, Arbutus Biopharma, Jumia Technologies, Bright Health Group, or Argo Blockchain?
NEW YORK, Dec. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ABUS, JMIA, BHG, and ARBK.
Dec 06, 2021 04:05 pm ET
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from the pivotal, Phase 3 Lavender™ study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. On the Rett Syndrome Behaviour Questionnaire (RSBQ), change from baseline to week 12 was -5.1 vs. -1.7 (p=0.0175; effect size=0.37). The Clinical Global Impression–Improvement (CGI-I) score at week 12 was 3.5 vs.
Dec 01, 2021 09:00 am ET
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that The Lancet Psychiatry published results from the Phase 2 ADVANCE study. ADVANCE was an international, 26-week, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of adjunctive pimavanserin treatment in outpatients with moderate-to-severe predominant negative symptoms of schizophrenia who had achieved control of positive symptoms with their ongoing antipsychotic treatment.
Nov 16, 2021 09:00 am ET
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the national launch of Yours, Truly, a multicultural, storytelling campaign to bring greater awareness and understanding of the varied experiences of the non-motor symptoms associated with Parkinson’s disease. In collaboration with StoryCorps, the campaign provides the Parkinson’s disease community a unique forum to record, share and archive their personal stories, in both Spanish and English, while also seeking to reduce the stigma around non-motor symptoms by sharing personal experiences. Available at
Nov 08, 2021 04:05 pm ET
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.
Nov 02, 2021 09:00 am ET
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX. The presentations demonstrate the suboptimal outcomes associated with the off-label use of currently available atypical antipsychotic treatments in managing dementia-related hallucinations and delusions, along with the related cost burdens.
Nov 01, 2021 04:05 pm ET
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice President, Chief Insights and Analytics Officer, will continue to report to Steve Davis, Chief Executive Officer and continue to serve as a member of the company’s Executive Management Committee. He will assume responsibility for all sales and marketing functions, in addition to his current responsibilities leading commercial strategy, operations, patient services, and marke
Oct 27, 2021 09:00 am ET
Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 8, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Oct 25, 2021 09:00 am ET
Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Con
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a scientific presentation on pimavanserin for the treatment of hallucinations and delusions in patients with Parkinson’s disease dementia will be shared at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held virtually and in-person November 9-12, 2021 in Boston, MA.
Sep 02, 2021 09:00 am ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
Sep 01, 2021 04:05 pm ET
Acadia Pharmaceuticals Announces Executive Leadership Change
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia’s interim Chief Financial Officer. The company is conducting a formal search for a new CFO.
Aug 06, 2021 01:54 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD), ChemoCentryx, Inc. (NasdaqGS: CCXI), and Peloton Interactive, Inc (Nasd
3D Systems Corp. (NYSE: DDD) Lifshitz Law Firm, P.C. announces that a class action complaint was filed against DDD alleging that DDD made false and/or misleading statements and/or failed to disclose that: (1) DDD lacked proper internal controls...
Aug 05, 2021 04:05 pm ET
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p.m. Eastern Time.
Aug 04, 2021 04:05 pm ET
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
Jul 21, 2021 05:05 pm ET
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigati
Jul 21, 2021 09:00 am ET
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Jul 14, 2021 09:00 am ET
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually.
Jun 20, 2021 12:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers.   The class action, filed in the United States District Court for the...
Jun 20, 2021 10:25 am ET
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. (“Acadia” or “the Company”) (NASDAQ:
Jun 19, 2021 08:26 am ET
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. (“Acadia” or “the Company”) (NASDAQ:
Jun 17, 2021 09:36 am ET
ACAD SHAREHOLDER DEADLINE TOMORROW: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Jun 16, 2021 10:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jun 16, 2021 11:00 am ET
Two Days Left to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 15, 2021 12:43 pm ET
Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) investors that acquired shares between June 15, 2020 - Apr. 4, 2021. Investors have until June 18, 2021 to...
Jun 15, 2021 11:15 am ET
DEADLINE ALERT for FUV, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 14, 2021 07:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers.   The class action, filed in the United States District Court for the...
Jun 14, 2021 11:00 am ET
DEADLINE ALERT for ACAD, CCIV, PINS, VWAGY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 14, 2021 10:00 am ET
FUV, ACAD & EBS Few Days Left to Actively Participate in Class Actions: Bronstein, Gewirtz & Grossman LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 14, 2021 09:00 am ET
Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) investors that acquired shares between June 15, 2020 - Apr. 4, 2021. Investors have until June 18, 2021 to...
Jun 12, 2021 11:16 am ET
ACAD 6-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Deadline Approaching in Securities Class Action
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Jun 11, 2021 11:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”). Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jun 11, 2021 11:47 am ET
ACAD BREAKING ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 18 Deadline in Securities C
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”) of the important June 18, 2021 lead plaintiff deadline.
Jun 10, 2021 11:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD
NEW YORK, June 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of its officers.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"), seeking to recover damage
Jun 10, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:...
Jun 09, 2021 10:00 am ET
FUV, ACAD & EBS Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines: June 18, 2021
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 08, 2021 06:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
Jun 08, 2021 11:45 am ET
DEADLINE ALERT for FUV, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 08, 2021 08:00 am ET
Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) investors that acquired shares between June 15, 2020 - Apr. 4, 2021. Investors have until June 18, 2021 to...
Jun 07, 2021 03:04 pm ET
ACAD 11-DAY DEADLINE ALERT: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Before the June 18th Deadline in Securities Fraud Lawsuit
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Jun 07, 2021 11:30 am ET
DEADLINE ALERT for ACAD, CCIV, PINS, VWAGY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jun 03, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:...
Jun 03, 2021 11:26 am ET
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced publication of open-label extension (OLE) data from patients experiencing hallucinations and delusions associated with Parkinson’s disease psychosis (PDP) who had previously completed one of three, six-week, double-blind, placebo-controlled studies.
Jun 03, 2021 10:01 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD) and certain of its officers.  The class action, filed in the United States District Court for the...
Jun 03, 2021 09:00 am ET
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced publication of open-label extension (OLE) data from patients experiencing hallucinations and delusions associated with Parkinson’s disease psychosis (PDP) who had previously completed one of three, six-week, double-blind, placebo-controlled studies.
Jun 02, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intrusion, Inc. (NASDAQ: INTZ), Romeo Power, Inc. (NYSE: RMO), and Acadia...
Jun 02, 2021 05:16 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Jun 02, 2021 11:00 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 30, 2021 04:45 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action – ACAD
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021, inclusive (the...
May 28, 2021 09:35 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, June 18th Deadline Approaching in Securities Fraud Lawsuit
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 27, 2021 11:00 am ET
DEADLINE ALERT for ACAD, CCIV, PINS, VWAGY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 26, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MultiPlan Corporation, Intrusion, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to C
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MultiPlan Corporation (NYSE: MPLN), Intrusion, Inc. (NASDAQ: INTZ), Romeo Power,...
May 26, 2021 04:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
May 26, 2021 11:45 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 26, 2021 09:00 am ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:
May 25, 2021 08:00 am ET
Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) investors that acquired shares between June 15, 2020 - Apr. 4, 2021. Investors have until June 18, 2021 to...
May 23, 2021 11:21 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Acadia Pharmaceuticals (ACAD) Investors of Securities Fraud Lawsuit, Investors with Losses Secure Counsel
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 21, 2021 11:15 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 21, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:...
May 20, 2021 09:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
May 20, 2021 12:00 pm ET
DEADLINE ALERT for ACAD, CCIV, PINS, VWAGY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 19, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intrusion, Inc. (NASDAQ: INTZ), LifeMD, Inc. (NASDAQ: LFMD), Romeo Power, Inc....
May 19, 2021 10:00 am ET
LFMD, FUV & ACAD Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 18, 2021 11:53 am ET
HAGENS BERMAN Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm, Securities Fraud Class Action Filed
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 14, 2021 11:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
May 14, 2021 12:05 pm ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intrusion, Inc. (NASDAQ: INTZ), LifeMD, Inc. (NASDAQ: LFMD), Romeo Power, Inc....
May 13, 2021 01:46 pm ET
ACAD INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 12, 2021 11:00 am ET
DEADLINE ALERT for NEPT, BLU, ACAD, PINS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 08, 2021 07:52 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD) and certain of its officers.   The class action, filed in the United States District Court for the...
May 08, 2021 11:10 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
May 07, 2021 11:00 am ET
DEADLINE ALERT for FUV, EBS, ACAD, and CCIV: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 06, 2021 11:31 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:...
May 05, 2021 10:14 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intrusion, Inc. (NASDAQ: INTZ), LifeMD, Inc. (NASDAQ: LFMD), Romeo Power, Inc....
May 05, 2021 04:10 pm ET
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021.
May 04, 2021 09:00 am ET
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:
May 03, 2021 09:52 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action and Application Deadline, Encourages Investors with Losses to Contact Its Attorneys N
Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 18, 2021Visit:...
Apr 30, 2021 10:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the...
Apr 30, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ:
Apr 30, 2021 11:00 am ET
DEADLINE ALERT for FUV, EBS, and ACAD: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 29, 2021 11:00 am ET
ACAD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 28, 2021 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intrusion, Inc. (NASDAQ: INTZ), LifeMD, Inc. (NASDAQ: LFMD), Romeo Power, Inc....
Apr 28, 2021 11:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
Law Offices of Howard G. Smith reminds investors of the upcoming June 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD) securities between June 15, 2020 and April 4, 2021, inclusive (the “Class Period”).

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.